BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 8526754)

  • 1. [Various immunohistochemical markers of precancer and variants of prostate cancer].
    Romanenko AM; Vorob'eva LR
    Arkh Patol; 1995; 57(4):38-41. PubMed ID: 8526754
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Production of serum-free and total prostate-specific antigen due to prostatic intraepithelial neoplasia.
    Minardi D; Galosi AB; Dell'Atti L; Hanitzsch H; Mario P; Muzzonigro G
    Scand J Urol Nephrol; 2002; 36(5):323-9. PubMed ID: 12487735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A theoretical rationale on the histogenesis of premalignant lesions and early carcinoma of the prostate.
    Botticelli AR
    Pathologica; 1994 Apr; 86(2):128-41. PubMed ID: 7524011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunohistochemical expression of retinoblastoma and p53 tumor suppressor genes in prostatic intraepithelial neoplasia: comparison with prostatic adenocarcinoma and benign prostate.
    Tamboli P; Amin MB; Xu HJ; Linden MD
    Mod Pathol; 1998 Mar; 11(3):247-52. PubMed ID: 9521470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of transrectal ultrasound and prostate-specific antigen in diagnosis of prostatic intraepithelial neoplasia.
    Lee F; Torp-Pedersen ST; Carroll JT; Siders DB; Christensen-Day C; Mitchell AE
    Urology; 1989 Dec; 34(6 Suppl):4-8. PubMed ID: 2481362
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Applications of immunohistochemistry to the diagnosis and prognostication of prostate carcinoma and prostatic intraepithelial neoplasia.
    Maygarden SJ
    Pathol Annu; 1994; 29 Pt 1():303-20. PubMed ID: 7510385
    [No Abstract]   [Full Text] [Related]  

  • 7. [Study of alpha1-antichymotrypsin (ACT) in prostatic carcinoma].
    Karseladze AI; Rytin IE; Matveev VB
    Arkh Patol; 2005; 67(1):30-3. PubMed ID: 15822791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Critical-laboratoristic correlation of the diagnostic importance of prostate specific antigen compared with prostatic acid phosphatase and carcinoembryonic antigen in the prostatic cancer.
    Milani M; Tacconi R; Marsili G; Trognoni A; Centioni G; Leoni T; Fumarola A
    Quad Sclavo Diagn; 1986 Dec; 22(4):428-32. PubMed ID: 2445000
    [No Abstract]   [Full Text] [Related]  

  • 9. Premalignant lesions of prostate and their association with nodular hyperplasia and carcinoma prostate.
    Rekhi B; Jaswal TS; Arora B
    Indian J Cancer; 2004; 41(2):60-5. PubMed ID: 15318010
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The significance of serum prostate-specific antigen, gamma-seminoprotein and prostatic acid phosphatase as prostate cancer markers].
    Yamaguchi K; Tanaka M; Kitagawa N; Kotake T; Yanagi S; Ito H
    Hinyokika Kiyo; 1989 Jun; 35(6):987-91. PubMed ID: 2478006
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostatic intraepithelial neoplasia (PIN) and other prostatic lesions as risk factors and surrogate endpoints for cancer chemoprevention trials.
    Bostwick DG; Aquilina JW
    J Cell Biochem Suppl; 1996; 25():156-64. PubMed ID: 9027613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of alpha-methylacyl-coA racemase among men with high grade prostatic intraepithelial neoplasia in prostate biopsies.
    Stewart J; Fleshner N; Cole H; Toi A; Sweet J
    J Urol; 2008 May; 179(5):1751-5; discussion 1755. PubMed ID: 18343427
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Free and total serum PSA values in patients with prostatic intraepithelial neoplasia (PIN), prostate cancer and BPH. Is F/T PSA a potential probe for dormant and manifest cancer?
    Tarle M; Kraljić I
    Anticancer Res; 1997; 17(3A):1531-4. PubMed ID: 9179191
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Putative preneoplastic foci in the human prostate.
    Pretlow TG; Nagabhushan M; Sy M; Guo Y; Pretlow TP
    J Cell Biochem Suppl; 1994; 19():224-31. PubMed ID: 7529854
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of androgen receptor and growth factors in premalignant lesions of the prostate.
    Harper ME; Glynne-Jones E; Goddard L; Mathews P; Nicholson RI
    J Pathol; 1998 Oct; 186(2):169-77. PubMed ID: 9924433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate-specific antigen and prostate-specific acid phosphatase in neuroendocrine cells of prostate cancer.
    Cohen RJ; Glezerson G; Haffejee Z
    Arch Pathol Lab Med; 1992 Jan; 116(1):65-6. PubMed ID: 1370878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-grade prostatic intraepithelial neoplasialike ductal adenocarcinoma of the prostate: a clinicopathologic study of 28 cases.
    Tavora F; Epstein JI
    Am J Surg Pathol; 2008 Jul; 32(7):1060-7. PubMed ID: 18496142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Premalignant and benign lesions in nodules of adenomatous hyperplasia].
    Miján Ortiz JL; Fernández Rodríguez A; Fernández Ruiz PL; de la Fuente Serrano A; Nogales Fernández F; Zuluaga Gómez A
    Arch Esp Urol; 1996 Sep; 49(7):684-7. PubMed ID: 9020004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Markers for the development of early prostate cancer.
    Slater MD; Lauer C; Gidley-Baird A; Barden JA
    J Pathol; 2003 Mar; 199(3):368-77. PubMed ID: 12579539
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of prostate-specific antigen in the chemoprevention of prostate cancer.
    Crawford ED; DeAntoni EP; Ross CA
    J Cell Biochem Suppl; 1996; 25():149-55. PubMed ID: 9027612
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.